Life sciences firms are moving beyond traditional industry boundaries to create new health care solutions for patients and providers. By combining life sciences' core technologies (diagnostics, devices and drugs) in innovative ways, firms are creating new technology platforms and products that offer improvements in safety, effectiveness, convenience and value. These convergent solutions are also providing life sciences companies with new avenues for innovation, growth and differentiation. 

Convergence is occurring at all stages of the value chain and through various approaches. Life sciences companies must make several strategic decisions in choosing and managing the convergence pathway. This new paper from Deloitte Research highlights various examples of convergence, identifies the driving forces behind the trend and discusses the pathways to convergence in the marketplace today. The report also proposes a framework for considering investment alternatives under different scenarios of technological uncertainty, as well as strategies for choosing a specific convergence pathway, managing successful cross-sector partnerships and alliance networks and addressing regulatory challenges. Learn more from the full report, available at the bottom of this page in PDF format.

Related content
Interview: Life Sciences Industry — Converging for Better Care